BPTC Promotes Jones and Ransohoff to Principal Consultants - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BPTC Promotes Jones and Ransohoff to Principal Consultants


Bioprocess Technology Consultants, Inc. (BPTC) a strategic, technical, and regulatory consulting company for the biopharmaceutical industry, has promoted Susan Dana Jones, PhD, and Thomas C. Ransohoff to principal consultants. As vice-presidents and principal consultants, they will continue to head client programs as well as assume greater management roles within the company.

Jones, who joined BPTC in 2002, is the co-founder of three l biotechnology companies and is known for her expertise in cell line development, cell culture, and process development for biopharmaceutical and vaccine products. She has managed multiple discovery and product development programs, and advises clients on manufacturing and regulatory issues. She is a member of the board of directors of Gene Solutions, LLC, the Symphogen A/S scientific advisory board, and the editorial advisory board of BioProcess International. Prior to joining BPTC, she was senior vice president of corporate development at Serenex, Inc. She received her bachelor of science degree in biochemistry from Harvard University, holds a doctorate in genetics from the University of California, San Francisco, and performed post-doctoral research at the Dana-Farber Cancer Institute of Harvard Medical School.

Ransohoff, who joined BPTC in 2002, has over 25 years of experience in the biopharmaceutical industry with expertise in the development and scale-up of biopharmaceutical processes; separations and purification technologies; process economic modeling; cGMP manufacturing; and management of technology-based start-up ventures. He guides clients through all stages of product development, advising on CMC strategy including regulatory, commercial, and manufacturing decisions. He is the cofounder of two biotechnology companies, and previously held senior level positions at TranXenoGen, Dyax, and Repligen. Ransohoff is a member of the editorial advisory board of BioPharm Magazine, and has served on a number of scientific and professional advisory boards. He has a bachelor of science degree from MIT and an Master’s degree from the University of California, Berkeley, both in Chemical Engineering.

Source: Bioprocess Technology Consultants

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here